We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Different Test Systems Analytical Performance Evaluated for Serum Creatinine

By LabMedica International staff writers
Posted on 13 Jan 2022
Print article
Image: The cobas CREP2 reagent kit: an in vitro test for the quantitative determination of creatinine in serum, human plasma and urine (Photo courtesy of Roche Diagnostics)
Image: The cobas CREP2 reagent kit: an in vitro test for the quantitative determination of creatinine in serum, human plasma and urine (Photo courtesy of Roche Diagnostics)
Creatinine is a breakdown product of creatine phosphate from muscle and protein metabolism. It is produced and released by the body at a constant rate into the blood, and it is then carried to the kidneys through the blood circulation.

In clinical practice, the level of serum creatinine (SCr) is generally used as a significant indicator for renal function evaluation. SCr determination is a widely applied diagnostic test to evaluate glomerular filtration rate (GFR) that when renal function is impaired, the creatinine level rises. Clinical methods for serum creatinine determination include chemical and enzymatic methods.

Clinical Laboratorians at the University of Chinese Medicine (Guangzhou, China) obtained serum samples by collecting surplus samples from routine creatinine tests. Specimens for method comparison study were collected from left-over clinical 34 patient samples, with creatinine levels ranging from 45 to 1,610 μmol/L. Precision, accuracy, linearity, dilution, lower limit of measurement and analytical interference were studied between two test systems.

The scientists used the open test system, namely the Shino-Test creatinine reagent kit (Shino-Test Corp., Tokyo, Japan), and the Roche Cobas 8000 c702 chemistry analyzer (Roche Diagnostics, Mannheim, Germany) to determine creatinine levels. The determination results were analyzed and compared with those obtained from the matched test system, Roche creatinine reagent kit and the same analyzer. An interference study was carried out by adding different solutions of interferents to serum pools at three levels of creatinine. To study the influence of hemolysis, hemolysate was added to each serum pool aliquot. Interference studies of vitamin C or dobutamine were carried out by mixing serum pool aliquots with serial dilutions of vitamin C solution or dobutamine injection.

The investigators reported that the performance of SCr from the open test system was in compliance with the matched test system with good precision, accuracy, and linearity. In presence of most common interferents, both test systems could lead to accurate creatinine results except for the existence of specified drugs. For dobutamine, the open test system showed better anti-interference performance than the matched system. The results showed that either matched test system or open test system presented extremely low imprecision at each level evaluated.

The authors concluded that their study provided referable opinions for clinical laboratory selection on the test system and a framework for future analogous studies based on different test systems. Clinicians and laboratory professionals should be mindful of potential interference caused by specified medications such as calcium dobesilate and dobutamine because an inaccurate creatinine result may lead to serious untoward consequences. The study was published on December 26, 2021 in the Journal of Clinical Laboratory Analysis.

Related Links:
University of Chinese Medicine
Shino-Test Corp
Roche Diagnostics


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more